Mark S. Luer

765 total citations
27 papers, 592 citations indexed

About

Mark S. Luer is a scholar working on Neurology, Pediatrics, Perinatology and Child Health and Surgery. According to data from OpenAlex, Mark S. Luer has authored 27 papers receiving a total of 592 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Neurology, 6 papers in Pediatrics, Perinatology and Child Health and 5 papers in Surgery. Recurrent topics in Mark S. Luer's work include Traumatic Brain Injury and Neurovascular Disturbances (8 papers), Pharmacological Effects and Toxicity Studies (5 papers) and Epilepsy research and treatment (4 papers). Mark S. Luer is often cited by papers focused on Traumatic Brain Injury and Neurovascular Disturbances (8 papers), Pharmacological Effects and Toxicity Studies (5 papers) and Epilepsy research and treatment (4 papers). Mark S. Luer collaborates with scholars based in United States and Belgium. Mark S. Luer's co-authors include Manuel Dujovny, Denise H. Rhoney, Jimmi Hatton, James I. Ausman, Clement Hamani, Konstantin V. Slavin, Mildred D. Gottwald, Glen T. Schumock, Richard Scheife and Aaron H. Burstein and has published in prestigious journals such as Journal of neurosurgery, Neurosurgery and Clinical Pharmacology & Therapeutics.

In The Last Decade

Mark S. Luer

27 papers receiving 561 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark S. Luer United States 16 186 125 98 79 69 27 592
E. Hokkanen Finland 18 220 1.2× 81 0.6× 85 0.9× 76 1.0× 72 1.0× 66 830
Cahide Yılmaz Türkiye 15 91 0.5× 110 0.9× 107 1.1× 61 0.8× 115 1.7× 46 599
Chi‐Ren Huang Taiwan 14 72 0.4× 82 0.7× 160 1.6× 64 0.8× 225 3.3× 22 708
H.‐J. Dieterich Germany 19 62 0.3× 154 1.2× 131 1.3× 45 0.6× 50 0.7× 52 900
David W. Amory United States 21 111 0.6× 386 3.1× 212 2.2× 71 0.9× 38 0.6× 58 1.1k
Amit Prasad United States 15 68 0.4× 172 1.4× 136 1.4× 95 1.2× 16 0.2× 38 617
J. Mühling Germany 19 54 0.3× 234 1.9× 143 1.5× 62 0.8× 32 0.5× 59 1.0k
Xiujuan Wu China 15 312 1.7× 92 0.7× 147 1.5× 208 2.6× 22 0.3× 49 847
Stephen Boone United States 12 777 4.2× 70 0.6× 116 1.2× 152 1.9× 41 0.6× 30 1.2k
Daniel Kanter United States 10 331 1.8× 50 0.4× 161 1.6× 50 0.6× 24 0.3× 15 895

Countries citing papers authored by Mark S. Luer

Since Specialization
Citations

This map shows the geographic impact of Mark S. Luer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark S. Luer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark S. Luer more than expected).

Fields of papers citing papers by Mark S. Luer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark S. Luer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark S. Luer. The network helps show where Mark S. Luer may publish in the future.

Co-authorship network of co-authors of Mark S. Luer

This figure shows the co-authorship network connecting the top 25 collaborators of Mark S. Luer. A scholar is included among the top collaborators of Mark S. Luer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark S. Luer. Mark S. Luer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schober, Joseph, Theresia Weber, Phuong T. K. Nguyen, et al.. (2012). β-cell metabolic alterations under chronic nutrient overload in rat and human islets. Islets. 4(6). 379–392. 54 indexed citations
2.
Luer, Mark S., et al.. (2004). Fluctuations in vancomycin CNS tissue concentrations following intermittent and continuous infusions in the rat. Neurological Research. 26(3). 312–315. 4 indexed citations
3.
Luer, Mark S., et al.. (2002). Ischemic stroke prevention: An update on antiplatelet therapy. Neurological Research. 24(4). 381–388. 6 indexed citations
4.
Scheife, Richard, Glen T. Schumock, Aaron H. Burstein, Mildred D. Gottwald, & Mark S. Luer. (2000). Impact of Parkinson’s disease and its pharmacologic treatment on quality of life and economic outcomes. American Journal of Health-System Pharmacy. 57(10). 953–962. 51 indexed citations
5.
Luer, Mark S.. (1999). Interventions to Achieve Tonic Exposure to Levodopa: Delaying or Preventing the Onset of Motor Complications. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 19(11P2). 169S–79S. 2 indexed citations
6.
Luer, Mark S., Clement Hamani, Manuel Dujovny, et al.. (1999). Saturable transport of gabapentin at the blood-brain barrier. Neurological Research. 21(6). 559–562. 41 indexed citations
7.
Luer, Mark S.. (1998). Fosphenytoin. Neurological Research. 20(2). 178–182. 38 indexed citations
8.
Fischer, James H., et al.. (1997). Stability of Fosphenytoin Sodium with Intravenous Solutions in Glass Bottles, Polyvinyl Chloride Bags, and Polypropylene Syringes. Annals of Pharmacotherapy. 31(5). 553–559. 15 indexed citations
9.
Hamani, Clement, Mark S. Luer, & Manuel Dujovny. (1997). Microdialysis in the human brain: Review of its applications. Neurological Research. 19(3). 281–288. 34 indexed citations
10.
Rapp, Robert P., Kenneth A. Kudsk, R O Brown, et al.. (1997). Intravenous insulin-like growth factor-I (IGF-I) in moderate-to-severe head injury: a Phase II safety and efficacy trial. Journal of neurosurgery. 86(5). 779–786. 54 indexed citations
11.
Akdemir, Gökhan, Mark S. Luer, Manuel Dujovny, & Mukesh Misra. (1997). Intraventricular atrial natriuretic peptide for acute intracranial hypertension. Neurological Research. 19(5). 515–520. 16 indexed citations
12.
Ryan, Melody, Denise H. Rhoney, Mark S. Luer, & Jimmi Hatton. (1997). New and Investigational Treatment Options for Ischemic Stroke. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 17(5). 959–969. 8 indexed citations
13.
Hatton, Jimmi, Robert P. Rapp, Kenneth A. Kudsk, et al.. (1997). Intravenous insulin-like growth factor-I (IGF-I) in moderate-to-severe head injury: a Phase II safety and efficacy trial. Neurosurgical FOCUS. 2(5). E9–E9. 6 indexed citations
14.
Luer, Mark S., et al.. (1996). New Pharmacologic Strategies for Acute Neuronal Injury. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 16(5). 830–848. 22 indexed citations
15.
Rhoney, Denise H., et al.. (1996). New Pharmacologic Approaches to Acute Spinal Cord Injury. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 16(3). 382–392. 17 indexed citations
16.
Dujovny, Manuel, et al.. (1995). Transcranial cerebral oximetry and carotid cavernous fistula occlusion. Acta Neurochirurgica. 133(1-2). 83–86. 11 indexed citations
17.
Hatton, Jimmi, et al.. (1994). Histamine Receptor Antagonists and Lipid Stability in Total Nutrient Admixtures. Journal of Parenteral and Enteral Nutrition. 18(4). 308–312. 8 indexed citations
18.
Slavin, Konstantin V., et al.. (1994). Clinical experience with transcranial cerebral oximetry. Surgical Neurology. 42(6). 531–539. 30 indexed citations
19.
Hatton, Jimmi, Mark S. Luer, & Robert P. Rapp. (1993). Growth Factors in Nutritional Support. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 13(1). 17–22. 6 indexed citations
20.
Luer, Mark S. & Jimmi Hatton. (1993). Appropriateness of Antibiotic Selection and Use in Laminectomy and Microdiskectomy. American Journal of Health-System Pharmacy. 50(4). 667–670. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Hokkanen Breakdown of academic impact, for papers by Cahide Yılmaz Breakdown of academic impact, for papers by Chi‐Ren Huang Breakdown of academic impact, for papers by H.‐J. Dieterich Breakdown of academic impact, for papers by David W. Amory Breakdown of academic impact, for papers by Amit Prasad Breakdown of academic impact, for papers by J. Mühling Breakdown of academic impact, for papers by Xiujuan Wu Breakdown of academic impact, for papers by Stephen Boone Breakdown of academic impact, for papers by Daniel Kanter
Rankless by CCL
2026